Grant: Doctoral Research Award: Canada Graduate Scholarships
Université Laval
$105,000.00
Determining the role of transcription factor Irf5 in regulating microglial transcriptional and cellular activities in the demyelinating brain
FY 2021-22
Summary
Most patients affected by multiple sclerosis (MS) end up developing a progressive form of MS. The exact way progressive MS evolves is still unclear, but many studies link the resulting disabilities to inflammation in the patient's brain. Indeed, the brain has its own immune cells, the main type being called microglia. Those normally help in the process of remyelination, which coats the axons with a protective layer of lipids, the myelin. However, inflammation disrupts microglia's ability to help remyelination and can damage the axons.
We have found that microglia have a high quantity of a pro-inflammatory protein called Irf5 when myelin is being removed. It has also separately been shown that a high level of Irf5 produced by other immune cells impairs their repair functions. Therefore, we will study the activity of microglial Irf5 in the context of demyelination and remyelination.
The immune and nervous systems of mice are very similar to their human counterparts. This makes mice a good model to study diseases such as MS. We will use a treatment called cuprizone which will remove myelin in a reversible manner in mice whose microglia does not produce Irf5 and in others without this mutation as a control. At different time points, we will proceed to several analyses. First, we will characterize the contribution of Irf5 in demyelination and remyelination thanks to microscope imaging by observing myelin and microglia. Second, we will determine the molecular mechanisms behind the contribution of Irf5. To do so, we will isolate microglia and localize the sites of the genome that contribute to gene expression by means of bleeding edge sequencing techniques. Combining those analyses will lead to a well-defined portrait of microglial activity during demyelination.
In summary, this study could clarify elusive mechanisms of progressive MS and lead to new paths for detection and treatment, benefiting to any person affected by MS.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
458442
Name
Distéfano-Gagné Félix
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Determining the role of transcription factor Irf5 in regulating microglial transcriptional and cellular activities in the demyelinating brain
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Chip-Seq; Flow Cytometry; Irf5; Massively Parallel Sequencing; Microglia; Microscopy; Mouse Model; Multiple Sclerosis; Myelin; Rna-Seq
Abstract
Most patients affected by multiple sclerosis (MS) end up developing a progressive form of MS. The exact way progressive MS evolves is still unclear, but many studies link the resulting disabilities to inflammation in the patient's brain. Indeed, the brain has its own immune cells, the main type being called microglia. Those normally help in the process of remyelination, which coats the axons with a protective layer of lipids, the myelin. However, inflammation disrupts microglia's ability to help remyelination and can damage the axons.
We have found that microglia have a high quantity of a pro-inflammatory protein called Irf5 when myelin is being removed. It has also separately been shown that a high level of Irf5 produced by other immune cells impairs their repair functions. Therefore, we will study the activity of microglial Irf5 in the context of demyelination and remyelination.
The immune and nervous systems of mice are very similar to their human counterparts. This makes mice a good model to study diseases such as MS. We will use a treatment called cuprizone which will remove myelin in a reversible manner in mice whose microglia does not produce Irf5 and in others without this mutation as a control. At different time points, we will proceed to several analyses. First, we will characterize the contribution of Irf5 in demyelination and remyelination thanks to microscope imaging by observing myelin and microglia. Second, we will determine the molecular mechanisms behind the contribution of Irf5. To do so, we will isolate microglia and localize the sites of the genome that contribute to gene expression by means of bleeding edge sequencing techniques. Combining those analyses will lead to a well-defined portrait of microglial activity during demyelination.
In summary, this study could clarify elusive mechanisms of progressive MS and lead to new paths for detection and treatment, benefiting to any person affected by MS.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Distéfano-Gagné, Félix
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~